Doxorubicin (hydrochloride), CAS 25316-40-9

Product Description: Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].

Applications: Cancer-Kinase/protease

Formula: C27H30ClNO11

Citations: ACS Appl Mater Interfaces. 2020 Oct 21;12(42):47330-47341./ACS Appl Mater Interfaces. 2022 Aug 24./ACS Nano. 2020 Nov 24;14(11):15904-15918./Acta Pharmacol Sin. 2023 May 24./Adv Funct Mater. 10 October 2021./Adv Funct Mater. 23 October 2021./Adv Healthc Mater. 2020 Nov;9(22):e2001633./Adv Healthc Mater. 2021 Sep 8;e2101222./Adv Sci (Weinh). 2020 Sep 28;7(21):2001364./Advanced Therapeutics. 2021 Apr 14./Am J Cancer Res. 2021 Apr 15;11(4):1428-1445./Am J Transl Res. 2021 Sep 15;13(9):10112-10126./Anal Chim Acta. 2024 Jan 25, 1287, 342110./Angiogenesis. 2021 Jan 17./Ann Transl Med. 2020 Dec;8(23):1570./Anticancer Drugs. 2022 Mar 1;33(3):308-319./Arab J Chem. July 2022, 103934./Autophagy. 2021 Dec 10;1-19./Autophagy. 2021 Mar 22;1-17./Bioact Mater. 2024 May 11:38:384-398./Biochem Biophys Res Commun. 2019 Dec 10;520(3):544-550./Biochem Biophys Res Commun. 2020 Dec 10;533(3):304-312./Bioengineered. 2022 Apr;13(4):9467-9481./Biol Direct. 2023 Oct 9;18(1):63./Biomacromolecules. 2022 Sep 14./Biomater Adv. 17 October 2022, 213161./Biomed Pharmacother. 2020 Oct;130:110534./Biomed Pharmacother. 2021 May 29;140:111779./Biomed Pharmacother. 2021 May;137:111378./Biomed Pharmacother. 2021, 111308./Biomed Pharmacother. 2021, 111531./Biomed Pharmacother. 2024 Mar 2:173:116353./bioRxiv. 2020 Jun./bioRxiv. 2023 Feb 7./bioRxiv. 2023 Jan 13./bioRxiv. 2023 May 12./bioRxiv. 2023 Sep 16./bioRxiv. 2024 May 15./Breast Cancer Res Treat. 2021 Jul 8./Cancer Biol Med. 2021 Feb 15; 18(1): 184-198./Cancer Biol Med. 2021 Feb./Cancer Lett. 2021 Aug 10;S0304-3835(21)00395-5./Cancer Lett. 2022 Jun 28;536:215651./Cancer Sci. 2022 Jun;113(6):2008-2021./Cancers (Basel). 2021, 13(13), 3323./Cancers (Basel). 2022, 14(3), 683./Cell Death Differ. 2022 Jan 15./Cell Death Dis. 2020 Sep 15;11(9):756./Cell Death Dis. 2022 Aug 24;13(8):731./Cell Death Discov. 2021 Aug 5;7(1):204./Cell Metab. 2022 Feb 7;34(3):424-440.e7./Cell Rep. 2021 Aug 24;36(8):109568./Cell Rep. 2023 Mar 20;42(3):112275./Cell Rep. 2023, 42(1): 111916./Cell Stem Cell. 2021 Sep 14;S1934-5909(21)00343-X./Cell. 2024 Apr 25;187(9):2288-2304.e27./Cells. 2022 Dec 29;12(1):145./Cells. 2022, 11(17), 2642./Cells. 2023, 12(1), 145./Chem Biodivers. 2022 Sep 1./Chem Eng J. 2020, 127874./China Biotechnology. 2017, 37(4): 68-75./Circ Heart Fail. 2021 Oct;14(10):e008220./Colloid Interface Sci Commun. 2019 Jan;28:69-74. /Colloid Surface B. 2021, 111839./Colloids Surf B Biointerfaces. 2018 Jul 10;171:176-185./Colloids Surf B Biointerfaces. 2019 Jan 1;173:27-35./Colloids Surf B Biointerfaces. 2024 May 3:239:113937./Department of Pharmaceutical Sciences, University of Toronto. 2019 Oct./Dev Cell. 2018 Sep 24;46(6):681-695.e5./DNA Repair . 13 March 2022, 103319./Drug Deliv Transl Res. 2023 Mar 27./EBioMedicine. 2021 Jul;69:103456./Elife. 2022 May 3;11:e69255./Eur Heart J Open. 2023 Oct 9./Eur J Pharm Biopharm. 2018 Aug;129:88-103./Expert Opin Drug Deliv. 2021 Mar 11./FEBS Open Bio. 2021 Nov 14./Free Radic Biol Med. 2019 Jan;130:557-567./Free Radic Biol Med. 2021 Feb 1;163:141-152./Free Radic Biol Med. 2023 Apr 24;S0891-5849(23)00378-7./Free Radical Bio Med. 2021 Jan 6./Front Cell Dev Biol. 2021 Dec 24;9:781792./Front Endocrinol (Lausanne). 2018 Mar 22;9:120. /Harvard Medical School LINCS LIBRARY/Heliyon. 2023 Jul 13./Hepatology. 2020 May;71(5):1660-1677. /Hereditas. 2023 Oct 31;160(1):36./Inorganica Chimica Acta. 468 (2017) 270-279./Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264./Int Immunopharmacol. 2024 May 10:134:112197./Int J Biol Sci. 2021 Jul 25;17(12):3255-3267./Int J Med Sci. 2021 Jan 1;18(2):325-334./Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. /Int J Mol Sci. 2022 Nov 19;23(22):14385./Int J Mol Sci. 2023 Dec 25, 25(1), 312./Int J Mol Sci. 2024 Mar 7, 25(6), 3101./Int J Nanomedicine. 2024 Jan 5./Int J Oncol. 2023 Feb 8./Int J Pharm. 2022 May 25;620:121761./Int J Pharm. 2023 Feb 24;122779./Int J Pharm. 2024 Feb 11:653:123894./Int J Radiat Oncol Biol Phys. 2022 Jul 30;S0360-3016(22)02596-2./Iran J Med Sci. 2024 Apr 30./J Biochem Mol Toxicol. 2022 Apr 25:e23077./J Biomater Sci Polym Ed. 2018 Aug;29(12):1482-1497. /J Biomater Sci Polym Ed. 2021 Mar 11;1-13./J Bone Oncol. October 2021, 100391./J Cardiovasc Transl Res. 2020 Jul 16. /J Cell Biol. 2023 Jan 2;222(1):e202202110./J Cell Physiol. 2021 Apr 26./J Control Release. 2019 Jun 26;307:247-260. /J Control Release. 2022 Feb 21;S0168-3659(22)00100-6./J Ethnopharmacol. 2022 Aug 31;115676./J Extracell Vesicles. 2022 Aug;11(8):e12255./J Hematol Oncol. 2021 Oct 29;14(1):178./J Immunother Cancer. 2022 Aug;10(8):e004006./J Med Chem. 2023 Jul 6./J Mol Med (Berl). 2019 Aug;97(8):1183-1193./J Nanobiotechnology. 2023 Feb 10;21(1):50./J Org Chem. 2021 Sep 16./J Transl Med. 2021 Mar 21;19(1):117./J Virol. 2021 May 26;JVI0076021./Journal of New Chinese Medicine. 2016(7):278-282./Lett Appl Microbiol. 2022 Feb 25./Mater Chem Phys. 2021, 124596./Mater Today Bio. 2023 Oct, 22, 100780./Materials Today Chemistry. March 2022, 100637./MedComm. 2021 Jun 3./Mol Cancer. 2024 May 9;23(1):83./Mol Carcinog. 2021 Apr 18./Mol Cell Biochem. 2021 Feb;476(2):1233-1243./Mol Med Rep. 2020 Aug;22(2):915-925./Mol Ther. 2019 May 8;27(5):1051-1065. /Nanoscale Res Lett. 2018 Nov 3;13(1):350. /Nanotheranostics. 2021 Jan 1;5(2):143-154./Nanotheranostics. 2021; 5(2): 143-154./Nat Cell Biol. 2020 Sep;22(9):1056-1063./Nat Commun. 2018 Oct 8;9(1):4139. /Nat Commun. 2023 Apr 13;14(1):2109./Nat Med. 2016 May;22(5):547-56. /Nat Prod Commun. 2024 Mar 20./Nat Protoc. 2021 Jan;16(1):405-430./Nature. 2023 Jun;618(7964):374-382./Neuropharmacology. 2024 May 2:109981./NPJ Breast Cancer. 2022 May 6;8(1):60./Oncogene. 2022 Jun 30./Oncotarget. 2017 Nov 24;8(67):111190-111212. /Oxid Med Cell Longev. 2022 Apr 5;2022:4740931./Oxid Med Cell Longev. 2023 Jan 14;2023:9966355./Patent. US20180185310A1./Patent. US20180185346A1./Patent. US20180185379A1./Patent. US20180185386A1./Patent. US20180185387A1./Patent. US20180185388A1/Patent. US20180185389A1./Patent. US20180193355A1./Patent. US20200085841A1 /Patent. US20200345752A1./Patent. US20210275477A1./Patent. US20220016148A1./Patent. US20230190773A1./Pathol Res Pract. January 2022, 153735./Pharmacol Res. 2021 Apr 30;169:105642./Pharmacol Res. 2024 May 9:204:107208./Phytochemistry. 2021 Jul 31;190:112892./Phytomedicine. 2022 Jan 29;99:153964./Phytomedicine. 2023 Jun 10, 154922./Phytomedicine. 2023 Mar 10./PLoS Pathog. 2020 Mar 24;16(3):e1008429./Polym Bull (Berl). 30 September 2022./Redox Biol. 2021 Aug 31;46:102120./Research Square Preprint. 2020 Jul./Research Square Preprint. 2021 Nov./Research Square Preprint. 2021 Sep./Research Square Preprint. 2023 Nov 25./Research Square Preprint. 2023 Sep 20./Sci Adv. 2023 Mar 10;9(10):eadd8539./Sci Transl Med. 2024 Apr 3;16(741):eadj5705./Shock. 2023 Jul 1;60(1):100-109./Signal Transduct Target Ther. 2023 Feb 3;8(1):51./Small. 2023 Feb 7;e2205606./Small. 2024 Jan 15:e2308265./SSRN. 2023 Aug 14./SSRN. 2023 Nov 28./Ther Deliv. 2017 Mar;8(5):249-264./Theranostics. 2020 May 17;10(15):6581-6598. /Thyroid. 2019 Jun;29(6):809-823. /TMR Modern Herbal Medicine. 2021 Jul./Transl Androl Urol. Jul 29, 2022./Transl Oncol. 2021 Nov 22;15(1):101272./Ulsan National Institute of Science and Technology. 2023 Aug./Universiti Tunku Abdul Rahman. 2023 Sep 11./University of Gothenburg. 2023 Jun 27./University of Szeged. Department of Biochemistry and Molecular Biology Faculty of Science and Informatics. 2020 Nov./ACS Omega. 2019 Jul 11;4(7):12036-12042./Acta Biomater. 2020 Jun;109:229-243./Acta Biomater. 2024 Apr 15:179:340-353./Adv Healthc Mater. 2019 Sep;8(18):e1900543./Adv Sci (Weinh). 2022 May;9(15):e2105894./Adv Sci (Weinh). 2022 Oct;9(30):e2201210./Adv Sci (Weinh). 2023 Mar 26;e2206007./Am J Physiol Cell Physiol. 2023 Nov 27./Anal Chem. 2022 Sep 19./Antioxid Redox Signal. 2023 Jun 2./Artif Cells Nanomed Biotechnol. 2023 Dec;51(1):120-130./Asian J Pharm Sci. 2024 Jan 12, 100884./BBA-Mol Cell Res. 2022: 119409./Biochem Biophys Rep. 2024 Mar, 37, 101639./Biochem Biophys Res Commun. 2019 Sep 24;517(3):538-544./Biochem Biophys Res Commun. 2020 Jan 15;521(3):596-602./Biochem Biophys Res Commun. 2023 Nov 18, 149244./Biochem Biophys Res Commun. 2023 Nov 24, 149314./Biochem Biophys Res Commun. 2024 Jan 25, 149582./Biochem Pharmacol. 2020 Apr;174:113795./Biochem Pharmacol. 2020 May;175:113888./Biochem Pharmacol. 2023 Aug 25;115769./Biochem Pharmacol. 2024 Mar 16:116142./Biochem Pharmacol. 2020 May;175:113856./Biochim Biophys Acta Mol Cell Res. 2022: 119411./Biofabrication. 2022 Apr 13;14(3)./Biomacromolecules. 2023 Jan 13./Biomaterials. 2023 Oct, 301, 122236./Biomed Pharmacother. 2020 Mar;123:109803./Biomed Pharmacother. 2023 Apr 13;162:114691./Biomed Pharmacother. 2023 Apr 21;162:114733./Biomed Pharmacother. 2023 Jan;157:114087./Biomed Pharmacother. 2023 Oct 6:168:115654./Biomolecules. 2022 Feb 12;12(2):299./Bioorg Chem. 17 October 2022, 106206./bioRxiv. 2023 Apr 14./bioRxiv. 2023 Feb 27./bioRxiv. 2023 Sep 5./BMC Cancer. 2019 Jun 18;19(1):602. /Br J Pharmacol. 2022 Jan 18./Breast Cancer Res Treat. 2023 May 19./Breast Cancer Res. 2023 Oct 4;25(1):115./Breast Cancer Res. 2024 Mar 19;26(1):48./Cancer Cell Int. 2019 Jul 12;19:179. /Cancer Lett. 2022 Nov 30;216028./Cancers (Basel). 2022, 14(13), 3068./Cancers (Basel). 2023 Feb 1;15(3):930./Carcinogenesis. 2022 Sep 30;bgac078./Cell Biochem Funct. 2022 Apr 29./Cell Biosci. 2022 Jan 6;12(1):6./Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8./Cell Death Differ. 2

• Artikelnummer: MEXHY-15142-100
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-15142-100
• Green Labware: Nein
• Verpackungseinheit: 100 mg
• Mengeneinheit: STK